GHENT, Belgium, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:ABLX] today announced that it has received notice of a €1.68 million in grant funding from the Flemish Agency for Innovation by Science and Technology (IWT) to help advance the Company’s first inhaled Nanobody®, ALX-0171, in infants. The grant funding, which is available over a period of one year, will also be used to explore novel applications of nebulised Nanobodies.
Help employers find you! Check out all the jobs and post your resume.
